Raymond J. Dingledine, PhD


Department of Pharmacology

Emory University School of Medicine

Office: 5001 Rollins Research Center

Phone: 404-727-5982

Fax: 404-712-9920

Email: rdingle@emory.edu

Additional Contact Information

Mailing Address:

Emory University School of Medicine

Department of Pharmacology
1510 Clifton Road, Rollins Research Center Room 5001

Atlanta, Georgia 30322-3090

Additional Websites


  • PhD, Stanford University, 1975
  • Postdoctoral Fellow, University of Cambridge, England, 1975-1977
  • Postdoctoral Fellow, University of Oslo, Norway, 1977-1978
  • Research Associate, Duke University, 1978
  • Assistant, Associate, Full Professor, University of North Carolina at Chapel Hill, 1978-1992
  • Visiting Scientist, The Salk Institute, 1990-91


Research Area:
Epilepsy; Genetic control of glutamate receptor function
Research Interests:
Glutamate receptors mediate the vast majority of excitatory synaptic transmission in the brain. A major research effort is focused on regulation of glutamate receptor-mediated synaptic transmission in the brain by the co-activation of selected G-protein coupled receptors. A second research emphasis involves the use of microarray and associated technologies to identify novel targets and pathways involved in the basic cellular and molecular mechanisms of epilepsy. These research interests converge and have highlighted a role for cyclooxygenase-2 (COX2) signaling pathways in the cognitive deficits, impaired synaptic inhibition, and eurodegeneration caused by seizures. We are currently exploring the consequences of conditional COX2 knockouts and are seeking the prostaglandin receptors responsible for each of these effects; we are employing a chemical biology approach to develop novel small molecule modulators of these receptors in an effort to interrupt the development of epilepsy. As a whole our work integrates information from a variety of experimental strategies to contribute to a better understanding of epilepsy, with broad implications for other brain disorders including stroke and schizophrenia.